Loading...

New Swedish study results at SABCS show DiviTum® blood test reduces waiting times for evaluating breast cancer treatment

Uppsala, Sweden, November 14, 2017. Results from a study of 142 women with newly diagnosed metastatic breast cancer will be presented by researchers from Lund University at the world’s biggest breast cancer conference in San Antonio, USA. The study demonstrates that the DiviTum® blood-based biomarker can provide more accurate prognosis than today’s standard methods. 

2017-11-21T07:02:51+00:00 November 14th, 2017 08:00|Press Release|

Anders Rylander, CEO Biovica comments the Q1 report

Biovica's CEO Anders Rylander summarizes the first quarter of the company's fiscal year 2017/18. The interview focuses on the latest recruitments that have been made during the quarter, the DiviTum technology, and regulatory approvals needed for the product in key markets. The interview ends with Anders Rylander commenting on the Biovica strategy until 2019. [...]

2017-09-04T10:12:16+00:00 September 4th, 2017 10:30|News|

Biovica extends patent protection on key markets

Uppsala, Sweden May 9 2017. Biovica has received a new patent in China as well as patent extension for the company's technology in the United States. Both of the patents refer to Biovica's method of measuring thymidine kinase activity on a real-time PCR platform. The Chinese patent is valid until 13 May 2031. The U.S. patent [...]

2017-05-09T13:41:06+00:00 May 9th, 2017 10:00|News|

Biovica participates at ASCO, June 2-6, Chicago

Biovica will attend the ASCO (American Society of Clinical Oncology) Annual Meeting, an event that brings together 30 000 global oncology professionals. During ASCO Biovica will meet Pharma companies and oncologists to share the latest insights from the ongoing clinical trial programme and collaborations. Biovica has also been invited to present the latest DiviTum® data at [...]

2017-05-02T09:35:13+00:00 May 2nd, 2017 09:35|News|